The glycogen synthase kinase-3β (GSK3β) pathway plays an important role in mediating
neuronal fate and synaptic plasticity. In Alzheimer's disease (AD), abnormal activation of this …

Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine kinase
that is particularly abundant in the CNS. Dysregulation of GSK-3 activity is believed to play a …

Alzheimer's disease (AD) is the most common form of neurodegenerative disorder with
dementia, accounting for approximately 70% of the all cases. Currently, 5.8 million people in …

Accumulation of β-amyloid (Aβ) deposits is a primary pathological feature of Alzheimer
disease that is correlated with neurotoxicity and cognitive decline. The role of glycogen …

Abnormalities in molecular signalling have been implicated in neurodegeneration. It is
emerging that glycogen synthase kinase‐3 (GSK‐3) is a key signalling molecule that …

The glycogen synthase kinase-3β (GSK3β) pathway plays a central role in Alzheimer's
disease (AD) and its deregulation accounts for many of the pathological hallmarks of AD …

Evidence from basic molecular biology has noted a critical role of GSK-3 in Alzheimer's
disease (AD) pathogenesis such as beta-amyloid (Aβ) production and accumulation, the …

Glycogen synthase kinase (GSK)-3 has been proposed as the link between the two
histopathological hallmarks of Alzheimer's disease, the extracellular senile plaques …

Alzheimer's disease (AD) has been associated with altered activity of glycogen synthase
kinase 3 (GSK3) isozymes, which are proposed to contribute to both neurofibrillary tangles …

Activation of glycogen synthase kinase-3 (GSK-3) can cause memory deficits as seen in
Alzheimer's disease, the most common age-associated dementia, but the mechanism is not …